NEW YORK (GenomeWeb) – Molecular diagnostics developer CombiMatrix announced today that it has priced an underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at $1,000 per unit.

The firm hopes to raise gross proceeds of $8 million, part of which it will use to repurchase and retire its Series E convertible preferred stock. The offering is expected to close on or about March 24. Ladenburg Thalmann & Co. served as the sole bookrunning manager and Aegis Capital served as lead manager for the transaction.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.